For 2019, EU/EEA countries reported five human Lyssavirus infections. Four human cases of travel-related rabies were reported by Italy, Latvia, Spain and Norway with exposure in Tanzania, India, Morocco and the Philippines, respectively. One locally-acquired fatal case of European bat lyssavirus (EBLV-1) infection was reported by France.
This report presents the results of the fourth round of the EQA on antimicrobial susceptibility testing (AST) for national public health laboratories for Campylobacter (Campylobacter EQA4-AST) within the Food‐ and Waterborne Diseases and Zoonoses Network (FWD-Net). The objectives of this EQA4-AST were to determine the accuracy of quantitative AST results reported by participants; to identify common laboratory problems related to the guidance in the EU protocol, and to assess the overall comparability of routinely collected AST data from national public health reference laboratories across Europe.
This report provides an analysis of the external quality assessment (EQA) for the antimicrobial susceptibility testing (AST) performance of laboratories participating in the European Antimicrobial Resistance Surveillance Network (EARS-Net) in 2019. A total of 952 laboratories (1–95 per country) from 30 EU/EEA countries participated in the EQA exercise.
Rabies is a deadly disease and endemic in over 100 countries. It causes around 59,000 human deaths annually, the vast majority in Asia and Africa. There are safe and effective human vaccines for pre- and post-exposure prophylaxis. With a prompt and proper post-exposure prophylaxis (PEP), exposed people have a survival rate close to 100%.
Data on antimicrobial resistance (AMR) in zoonotic and indicator bacteria from humans, animals and
food are collected annually by the EU Member States (MSs), jointly analysed by EFSA and ECDC and
reported in a yearly EU Summary Report.